---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004128"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:03:25.244370+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir plans Phase 3 posoleucel enrollment completion in 2023; $234M cash

## Summary
- Cash balance $234M as of Dec 31, 2022; FY 2023 operating expenses guided $150M-$170M.
- Enrollment completion for all three posoleucel Phase 3 trials expected by end of 2023; data readouts in 2024.
- Topline results from Phase 2 BKV treatment study in kidney transplant patients expected in Q1 2023.
- Final Phase 2 multi-virus prevention data presented at ASH 2022 showed substantially lower infection rates.
- CEO Diana Brainard to present at J.P. Morgan Healthcare Conference on Jan 10, 2023.

## SEC filing metadata
- accession: 0001193125-23-004128
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/0001193125-23-004128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/d422387d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004128
- JSON: https://secwatch.observer/filing/0001193125-23-004128.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004128.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).
  - Period: fiscal year 2023
  - Guidance: initiated
  - Result: guidance update
  source text: For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash stock compensation expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/0001193125-23-004128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.